Parth Parenteral Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 02-07-2024
- Paid Up Capital ₹ 2.00 Cr
as on 02-07-2024
- Company Age 37 Year, 1 Month
- Last Filing with ROC 31 Mar 2016
- Open Charges ₹ 26.38 Cr
as on 02-07-2024
- Satisfied Charges ₹ 3.34 Cr
as on 02-07-2024
- Revenue -51.65%
(FY 2016)
- Profit 99.30%
(FY 2016)
- Ebitda 99.69%
(FY 2016)
- Net Worth -0.69%
(FY 2016)
- Total Assets 22.05%
(FY 2016)
About Parth Parenteral
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2016. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 2.00 Cr.
The company currently has active open charges totaling ₹26.38 Cr. The company has closed loans amounting to ₹3.34 Cr, as per Ministry of Corporate Affairs (MCA) records.
Jayesh Shukla and Bhanuben Shukla serve as directors at the Company.
- CIN/LLPIN
U24231GJ1987PTC010097
- Company No.
010097
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Oct 1987
- Date of AGM
30 Sep 2016
- Date of Balance Sheet
31 Mar 2016
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Gandhi Nagar, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media
Who are the key members and board of directors at Parth Parenteral?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jayesh Shukla  | Director | 29-Oct-1987 | Current |
| Bhanuben Shukla | Additional Director | 26-Jul-1996 | Current |
Financial Performance of Parth Parenteral.
Parth Parenteral Private Limited, for the financial year ended 2016, experienced significant reduction in revenue, with a 51.65% decrease. The company also saw a substantial improvement in profitability, with a 99.3% increase in profit. The company's net worth dipped by a decrease of 0.69%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Parth Parenteral?
In 2016, Parth Parenteral had a promoter holding of 43.36% and a public holding of 56.64%. The company had 2 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Alps Pharmaceuticals Private LimitedInactive For E-Filing 44 years 8 monthsJayesh Shukla is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Dena Bank Creation Date: 16 Sep 2002 | ₹13.00 Cr | Open |
Dena Bank Creation Date: 11 Oct 1999 | ₹13.00 Cr | Open |
Gujarat State Financial Corp. Creation Date: 23 Jun 1988 | ₹2.75 M | Open |
How Many Employees Work at Parth Parenteral?
Parth Parenteral has a workforce of 33 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Parth Parenteral, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Parth Parenteral's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
